Assessing Cardiovascular Risk Factors and Selecting Agents to Successfully Treat Patients With Type 2 Diabetes Mellitus

No abstract is available for this paper.

• Publication year

  2011

• Venue

  The Journal of the American Osteopathic Association

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.7556/jaoa.2011.20036PMID 21813732
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Losartan

  2012cited by this paper
• Standards of Medical Care in Diabetes—2011

  2011cited by this paper
• Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

  2011cited by this paper
• Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61

  2011cited by this paper
• American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update : a report from the American Heart Association

  2011cited by this paper
• American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan.

  2011cited by this paper
• Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies

  2011cited by this paper
• Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

  2011cited by this paper
• Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

  2010cited by this paper
• Prevalence and trends in obesity among US adults, 1999-2008.

  2010cited by this paper
• Intensive glycemic control and cardiovascular disease: an update

  2010cited by this paper
• Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.

  2010cited by this paper
• Developing a System to Predict Laboratory-Confirmed Chlamydial and/or Gonococcal Urethritis in Adult Male Emergency Department Patients

  2010cited by this paper
• Stage-based interventions for smoking cessation.

  2010cited by this paper
• New Perspectives in Type 2 Diabetes, Cardiovascular Risk, and Treatment Goals

  2010cited by this paper
• A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

  2010cited by this paper
• Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

  2010cited by this paper
• Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.

  2010cited by this paper
• Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide

  2010cited by this paper
• Defining and achieving treatment success in patients with type 2 diabetes mellitus.

  2010cited by this paper
• Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.

  2010cited by this paper
• Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder

  2009cited by this paper
• Do specialized centers and specialists produce better outcomes for patients with chronic diseases than primary care generalists? A systematic review.

  2009cited by this paper
• Intensive glycemic control and the prevention of cardiovascular events:implications of the ACCORD,ADVANCE,and VA Diabetes Trials

  2009cited by this paper
• Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials

  2009cited by this paper
• The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus

  2009cited by this paper
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009cited by this paper
• Patient and treatment perspectives: Revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk

  2009cited by this paper
• Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database

  2009cited by this paper
• Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Glucose control and vascular complications in veterans with type 2 diabetes.

  2009cited by this paper
• Effect of a multifactorial intervention on mortality in type 2 diabetes.

  2008cited by this paper
• Managing Type 2 Diabetes: Going Beyond Glycemic Control

  2008cited by this paper
• Treatment Modalities of Obesity

  2008cited by this paper
• Nutrition Recommendations and Interventions for Diabetes

  2008cited by this paper
• The gap between guidelines and practice in the treatment of type 2 diabetes A nationwide survey in Norway.

  2008cited by this paper
• Effect of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

  2008cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

  2008cited by this paper
• Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study

  2007cited by this paper
• Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.

  2007cited by this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cited by this paper
• Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues

  2007cited by this paper
• Cardiovascular disease and modifiable cardiometabolic risk factors.

  2007cited by this paper
• Adherence, body mass index, and depression in adults with type 2 diabetes: the mediational role of diabetes symptoms and self-efficacy.

  2007cited by this paper
• Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease.

  2007cited by this paper
• Obesity and diabetes in the developing world--a growing challenge.

  2007cited by this paper
• Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association

  2007cited by this paper
• Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus

  2006cited by this paper
• Standards of medical care in diabetes.

  2006cited by this paper
• Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

  2006cited by this paper
• Efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes

  2006cited by this paper
• Management of Type 2 Diabetes in the Primary Care Setting: A Practice-Based Research Network Study

  2006cited by this paper
• Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes

  2006cited by this paper
• Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)

  2006cited by this paper
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• Type 2 diabetes in children and youth.

  2005cited by this paper
• The cardiovascular continuum and renin–angiotensin–aldosterone system blockade

  2005cited by this paper
• Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

  2005cited by this paper
• Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.

  2005cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Psychosocial problems and barriers to improved diabetes management: results of the Cross‐National Diabetes Attitudes, Wishes and Needs (DAWN) Study

  2005cited by this paper
• Obesity and the development of insulin resistance and impaired fasting glucose in black and white adolescent girls: a longitudinal study.

  2004cited by this paper
• Adipokines: inflammation and the pleiotropic role of white adipose tissue

  2004cited by this paper
• K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease

  2004cited by this paper
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

  2004cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• Economic costs of diabetes in the US in 2002.

  2003cited by this paper
• Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy

  2003cited by this paper
• Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

  2003cited by this paper
• Increases in clinically severe obesity in the United States, 1986-2000.

  2003cited by this paper
• The direct medical cost of type 2 diabetes.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

  2003cited by this paper
• Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

  2002cited by this paper
• Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

  2002cited by this paper
• Obesity and target organ damage: diabetes

  2002cited by this paper
• Lifetime costs of complications resulting from type 2 diabetes in the U.S.

  2002cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

  1999cited by this paper
• The renin-angiotensin-aldosterone system: a specific target for hypertension management.

  1999cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

  1998cited by this paper
• Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

  1998cited by this paper
• Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary

  1998cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• Behavioral risk factor surveillance system.

  1989cited by this paper
• Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

  1987cited by this paper
• Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

  1986cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Assessing Cardiovascular Risk in Patients with Diabetes: An Update

  2019cites this paper
• Effects of high-dose parenteral vitamin D therapy on lipid profile and blood pressure in patients with diabetic nephropathy: A randomized double-blind clinical trial.

  2017cites this paper
• Scriptaid enhances skeletal muscle insulin action and cardiac function in obese mice

  2017cites this paper
• Unraveling the concealed and calculated cardiovascular risks in diabetes

  2016cites this paper
• Association of Male Gender and Younger Age at Diagnosis of Type 2 Diabetes with more Atherogenic Lipid Profile

  2015cites this paper
• 2D-1H proton magnetic resonance spectroscopic imaging study on brain metabolite alterations in patients with diabetic hypertension

  2015cites this paper
• The Association between Non Soy Legume Consumption and Cardiovascular Risk Factors

  2015cites this paper
• Association of Male Gender and Younger Age at Diagnosis of Type 2 Diabetes with more Atherogenic

  2015cites this paper
• The primary care physician/nephrologist partnership in treating chronic kidney disease.

  2014cites this paper
• Association of Hypoglycemic Treatment Regimens With Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes

  2013cites this paper
• Multiple pharmacological interventions targeting cardiovascular disease risk factors in individuals with type 2 diabetes-systematic review

  2013cites this paper